The NHS under-invests at its peril

pharmafile | February 1, 2008 | Feature | |  NHS, healthcare, investment 

Related Content

PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres

PlaqueTec’s BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist …

Envirogen secures place on NHS Scotland reverse osmosis framework

Envirogen has been appointed to Lot 6, covering reverse osmosis (RO), of the national Decontamination …

AbbVie expands Oxford R&D facility with new £120m UK research commitment

AbbVie has expanded its Oxford research and development (R&D) facility with a new 12,000 sq …

The Gateway to Local Adoption Series

Latest content